<?xml version="1.0" encoding="UTF-8"?>
<p>In the general population, increased levels of FVIII or FIX are associated with increased risk of thrombosis 
 <sup>
  <xref rid="ref-112" ref-type="bibr">112</xref>â€“ 
  <xref rid="ref-117" ref-type="bibr">117</xref>
 </sup>. Supraphysiological levels of FVIII in the HA study raise safety concerns 
 <sup>
  <xref rid="ref-114" ref-type="bibr">114</xref>, 
  <xref rid="ref-115" ref-type="bibr">115</xref>, 
  <xref rid="ref-118" ref-type="bibr">118</xref>
 </sup>, since men with hemophilia are not protected from cardiovascular disease and remain at risk of thrombotic complications 
 <sup>
  <xref rid="ref-118" ref-type="bibr">118</xref>
 </sup>. In addition, there is no evidence that levels above 50% of normal are associated with pathological bleeding, and hemophilia carriers have decreased mortality due to ischemic heart disease 
 <sup>
  <xref rid="ref-119" ref-type="bibr">119</xref>
 </sup>. The relative short-term follow-up of HA patients expressing elevated levels of FVIII prevent firm conclusions on the safety of this finding.
</p>
